Intravesical Bacillus Calmette-Guerin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome.

ABSTRACT:

Objectives

Intravesical Bacillus Calmette-Guérin (BCG) treatment for superficial bladder cancer is interrupted in approximatively 8% of cases as a result of complications. The objective is to report the severe related complications of Bacillus Calmette-Guérin (BCG) following an intravesical instillation for bladder tumor encountered at our institution for the past 5 years.

Methods

Medical records of a tertiary teaching hospital, located in Beirut, Lebanon, were retrospectively analyzed from June 2014 to June 2019 searching for severe related complications of BCG. A comprehensive review of articles on this subject was conducted.

Results

The incidence of severe systemic adverse events related to BCG instillation was 1.5% (5 out of 332 patients). A total of five patients

SUBMITTER: Waked R 

PROVIDER: S-EPMC7016447 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature